文献速递临床试验与 GCP真实世界研究与卫生经济

SWiFT试验(全血用于一线创伤研究)——院前全血与标准治疗对危及生命创伤性出血患者的临床与成本效果:多中心随机对照试验研究方案

The SWiFT trial (Study of Whole Blood in Frontline Trauma)-the clinical and cost effectiveness of pre-hospital whole blood versus standard care in patients with life-threatening traumatic haemorrhage: study protocol for a multi-centre randomised controlled trial.
PubMed 文献 · Trials · 2023-11-14

SWiFT试验为多中心、优效性、开放标签随机对照试验,含内部预试验与试验内成本效果分析,计划在英国至少10家空中救护服务机构招募848例危及生命的创伤性大出血患者,比较院前去白细胞全血输注与标准成分输血对24小时内死亡或大量输血比例的影响,并评估90天成本效果。

要点

  • 院前全血与标准成分输血对创伤性大出血患者24小时内全因死亡或大量输血复合结局的优效性比较。
  • 计划招募848例,双侧检验把握度85%、Ⅰ类错误5%、1:1分配,含一次期中分析。
  • 同时评估以试验主要结局及90天质量调整生命年计算的增量成本效果比。

核心结论

  • 该试验旨在确定院前去白细胞全血输注是否优于标准治疗(成分输血)以降低24小时内死亡或大量输血的比例,结果尚未报告。

研究设计与样本

  • 多中心、优效性、开放标签随机对照试验,含内部预试验与试验内成本效果分析。
  • 招募任何年龄、遭受重大创伤性出血且由参与研究的空中救护服务机构接诊的患者。
  • 计划招募848例参与者;双侧检验把握度85%、Ⅰ类错误5%、1:1分配、一次期中分析需602例,考虑25%创伤性心搏骤停及额外5%脱落后样本量为848例。

主要发现

  • 早期输血可改善危及生命出血患者的生存,但院前最佳输血策略尚未确立。
  • 全血使用已有一定获益证据,但尚无随机对照试验探讨院前全血与成分输血对创伤性危及生命出血患者的临床与成本效果。

关键数值与推荐

  • 主要结局为随机化后24小时内创伤性出血参与者死亡(全因死亡)或接受大量输血的比例。
  • 将收集并分析多项次要临床、流程与安全性终点。
  • 成本(全血供应、医院、健康及更广泛照护资源使用)与结局数据将综合呈现针对试验主要结局的增量成本效果比及伤后90天每质量调整生命年的成本。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Early blood transfusion improves survival in patients with life-threatening bleeding, but the optimal transfusion strategy in the pre-hospital setting has yet to be established. Although there is some evidence of benefit with the use of whole blood, there have been no randomised controlled trials exploring the clinical and cost effectiveness of pre-hospital administration of whole blood versus component therapy for trauma patients with life-threatening bleeding. The aim of this trial is to determine whether pre-hospital leukocyte-depleted whole blood transfusion is better than standard care (blood component transfusion) in reducing the proportion of participants who experience death or massive transfusion at 24 h. METHODS: This is a multi-centre, superiority, open-label, randomised controlled trial with internal pilot and within-trial cost-effectiveness analysis. Patients of any age will be eligible if they have suffered major traumatic haemorrhage and are attended by a participating air ambulance service. The primary outcome is the proportion of participants with traumatic haemorrhage who have died (all-cause mortality) or received massive transfusion in the first 24 h from randomisation. A number of secondary clinical, process, and safety endpoints will be collected and analysed. Cost (provision of whole blood, hospital, health, and wider care resource use) and outcome data will be synthesised to present incremental cost-effectiveness ratios for the trial primary outcome and cost per quality-adjusted life year at 90 days after injury. We plan to recruit 848 participants (a two-sided test with 85% power, 5% type I error, 1-1 allocation, and one interim analysis would require 602 participants-after allowing for 25% of participants in traumatic cardiac arrest and an additional 5% drop out, the sample size is 848). DISCUSSION: The SWiFT trial will recruit 848 participants across at least ten air ambulances services in the UK. It will investigate the clinical and cost-effectiveness of whole blood transfusion versus component therapy in the management of patients with life-threatening bleeding in the pre-hospital setting. TRIAL REGISTRATION: ISRCTN: 23657907; EudraCT: 2021-006876-18; IRAS Number: 300414; REC: 22/SC/0072, 21 Dec 2021.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Smith JE, Barnard EBG, Brown-O'Sullivan C, et al. The SWiFT trial (Study of Whole Blood in Frontline Trauma)-the clinical and cost effectiveness of pre-hospital whole blood versus standard care in patients with life-threatening traumatic haemorrhage: study protocol for a multi-centre randomised controlled trial. Trials. 2023. PMID: 37964393. doi:10.1186/s13063-023-07711-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。